Mater Private Network Cork has adopted dual-energy ablation to treat ventricular arrhythmias, becoming one of the first hospitals in Ireland and the first in Munster to offer the specialist heart rhythm procedure. The clinical milestone gives cardiologists in the south of Ireland access to advanced technology previously restricted to a small number of international centers.
Targeting Deep-Seated Electrical Signals
Ventricular arrhythmias are abnormal heart rhythms originating in the heart’s lower chambers that can lead to cardiac arrest in serious cases. Treating these conditions is often challenging. Abnormal electrical signals can arise deep within the heart muscle or in difficult-to-reach locations.
Traditional procedures rely on radiofrequency ablation, which uses heat to target problematic tissue. The newly adopted dual-energy platform allows cardiologists to switch dynamically between radiofrequency and pulsed field energy during a single procedure.
The hospital’s adoption follows the first reported human use of dual-energy technology for a ventricular arrhythmia, which was detailed in a Mayo Clinic case report published in January 2026.
At Mater Private Cork, the procedure utilizes Johnson & Johnson’s Dual Energy THERMOCOOL SMARTTOUCH SF technology alongside 3D cardiac mapping to precisely pinpoint abnormal electrical activity.
Expanding Regional Access in Cork
Having two forms of energy available gives medical teams greater flexibility to choose the best approach depending on the specific location and tissue type, according to statements provided by Dr. Pauriah. Dr. Pauriah noted that the technology expands treatment options for complex heart rhythms and allows selected patients to access specialist care locally in Cork rather than traveling to Dublin or overseas.
Shifting Complex Care Beyond Dublin
This rollout aligns with a broader industry push to shift complex, low-volume cardiac interventions out of Dublin-centered national hubs and into regional hospitals. For the private healthcare sector, the adoption highlights how hospital groups are leveraging early access to emerging device technology to anchor complex cardiology services regionally.
- Endometriosis: Patients and Doctors Question Standard Treatments
- Penn State Researcher Wins Grant for Pediatric Leukemia Treatment Study
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- Michael Dell’s family office nears deal to take $4.1bn insurance broker private (newsylist.com)